Semanteon Capital Management LP Invests $302,000 in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Semanteon Capital Management LP acquired a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 32,864 shares of the medical technology company’s stock, valued at approximately $302,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. R Squared Ltd bought a new position in Alphatec in the 4th quarter worth approximately $29,000. Nisa Investment Advisors LLC boosted its holdings in Alphatec by 973.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after buying an additional 4,234 shares during the period. Newton One Investments LLC bought a new position in Alphatec in the 4th quarter worth approximately $50,000. XTX Topco Ltd bought a new position in Alphatec in the 3rd quarter worth approximately $69,000. Finally, AlphaQuest LLC bought a new position in Alphatec in the 4th quarter worth approximately $80,000. 66.35% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Alphatec in a report on Tuesday, January 14th. Barclays raised their price target on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a report on Thursday, February 27th. Finally, Piper Sandler raised their price target on shares of Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, February 27th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Insider Transactions at Alphatec

In related news, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction on Monday, January 13th. The shares were sold at an average price of $10.71, for a total value of $624,210.93. Following the transaction, the executive vice president now owns 502,311 shares in the company, valued at $5,379,750.81. This trade represents a 10.40 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the transaction, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. The trade was a 3.07 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 337,321 shares of company stock valued at $3,828,060. Insiders own 22.80% of the company’s stock.

Alphatec Stock Performance

NASDAQ ATEC opened at $9.93 on Friday. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $14.54. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company has a market capitalization of $1.43 billion, a P/E ratio of -7.76 and a beta of 1.39. The company has a fifty day moving average of $10.96 and a 200-day moving average of $8.83.

Alphatec (NASDAQ:ATEC) last posted its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The company had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. As a group, equities research analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.